Numerous novel therapies on the horizon that reduce TG by decreasing the activity of proteins that inhibit lipoprotein lipase such as apolipoprotein C-III and ANGPTL 3/4, including Volanesorsen (ASO Apo CIII) approved in Germany for FCS with high risk of pancreatitis, offer promise for the future. Here, LPL is linked to pancreatitis.